BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Annalisa Petrelli , Sabrina Rizzolio , Filippo Pietrantonio , Sara E Bellomo , Matteo Benelli , Loris De Cecco , Dario Romagnoli , Enrico Berrino , Claudia Orrù , Salvatore Ribisi , Daniel Moya-Rull , Cristina Migliore , Daniela Conticelli , Irene M Maina , Elisabetta Puliga , Violeta Serra , Benedetta Pellegrino , Alba Llop-Guevara , Antonino Musolino , Salvatore Siena , Andrea Sartore-Bianchi , Michele Prisciandaro , Federica Morano , Maria Antista , Uberto Fumagalli , Giovanni De Manzoni , Maurizio Degiuli , Gian Luca Baiocchi , Marco F Amisano , Alessandro Ferrero , Caterina Marchiò , Simona Corso , Silvia Giordano Cancer research（2023）
摘要
PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended.
更多 查看译文
关键词
parp inhibitors, gastric cancers responsive, germline mutations
AI 理解论文
溯源树
样例
